English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Hutchison MediPharma Starts Phase I Trial of Fourth Cancer Molecule

Feb. 21, 2012

The drug discovery company Hutchison MediPharma announced on February 22, 2012 that it has begun a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. The Phase I clinical trial will serve for the purpose of evaluating the safety, tolerance and initial efficacy to treat various cancers including lung cancer and gastric cancer.
Volitinib, the fourth cancer drug that the company has brought to clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co-licensing agreement for the molecule with AstraZeneca in a $140 million deal. AstraZeneca assumed responsibility for developing Volitinib outside of China.